Treatment of therapy-induced bowel disease

Through genetically modified lactic acid bacteria expressing proteins, the problem of enteritis treatment caused by ICI and radiation therapy is solved, effective reduction of intestinal diseases and fibrosis reversal, and new treatments for immune-mediated enteritis are provided.

CN118984713APending Publication Date: 2024-11-19ILYA PHARMA AB
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202280092872.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-03-28
Filing Date
2022-12-28
Publication Date
2024-11-19

AI Technical Summary

Technical Problem

Existing cancer treatments such as ICI and radiation therapy often cause immune-mediated enteritis, resulting in a decline in the quality of life of patients and the difficulty of treatment. The existing treatment tools are limited, especially when evaluating and treating enteritis caused by ICI, there is objectivity and effectiveness. Sexual problems.

Method used

Using genetically modified lactic acid bacteria, expressing proteins that promote inflammation regression and wound healing, such as CXCL12, CXCL17 and TGF-β, to treat or prevent enteropathy caused by ICI and radiation therapy, reducing disease activity and fiber through local immune regulation change.

Benefits of technology

Effectively reduce disease activity, crypt damage and epithelial shed in the colon, reverse disease progression, reduce intestinal fibrosis, and improve intestinal symptoms. It provides a novel treatment plan for enteritis caused by ICI and radiation therapy, avoiding the limitations of steroid treatment sex.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0005017774280000241
    Figure BDA0005017774280000241
  • Figure BDA0005017774280000251
    Figure BDA0005017774280000251
  • Figure HDA0005017774290000011
    Figure HDA0005017774290000011
Patent Text Reader

Abstract

The present invention provides lactic acid bacteria (LAB) engineered to express a therapeutic protein capable of promoting inflammation regression and / or wound healing for use in the treatment or prevention of therapy-induced bowel disease in a human or animal subject.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention generally relates to the treatment of intestinal diseases caused in a subject as a result of a therapy administered to the subject, for example in the treatment of cancer. In particular, the treatment comprises administering lactic acid bacteria recombinantly engineered to express a therapeutic protein capable of promoting resolution of inflammation and / or wound healing. Background Art

[0002] Various therapies administered to subjects for the treatment or management of clinical conditions, particularly including cancer, may produce harmful or undesirable side effects, particularly including side effects on the lower gastrointestinal (GI) tract. Enteropathy caused by such therapies may limit the utility of the relevant therapies and, more specifically, may result in significant patient morbidity.

[0003] The introduction of immune checkpoint inhibitors (ICIs) targeting cytotoxic T lymphocyte-associated protein 4 (CTLA-4), programmed cell death receptor 1 (PD-1), and programmed cell death ligand 1 (PD-L1) has improved the prognosis of many advanced cancers, including melanoma, urothelial carcinoma, renal cell carcinoma, and non-small cell lung cancer. Although ICI treatment may help responders effectively control tumors, many patients treated with ICIs experience immune-mediated adverse events such as enteritis, hepatitis, arthritis, dermatitis, thyroiditis, and hypophysitis.

[0004] In addition, although combined ICI is more effective for cancer control compared with monotherapy, this strategy is associated with a higher risk of immune-mediated adverse events, depending on the dose and duration of treatment. Up to one-third of patients treated with ICIs experience immune-mediated enteritis characterized by abdominal pain and diarrhea, which negatively affects the patient's quality of life and may limit the persistence of ICI treatment. However, for those patients who develop immune-related gastrointestinal adverse events (AEs), progression-free survival is also the longest, which also represents, for example, enhanced T lymphocyte activity under tumor immunosuppression. Therefore, effective prevention or treatment of ICI-induced enteritis is an important and inherent component of long-term tumor control plans.

[0005] Current guidelines recommend that ICI-induced colitis be treated based on the grade of presentation as assessed by the Common Terminology Criteria for Adverse Events (CTCAE). Supportive measures, systemic corticosteroids, temporary or permanent discontinuation of ICI therapy, and the TNF inhibitor infliximab are sequentially recommended and reported for progressively worsening disease. However, there is concern that TNF inhibitors may have a counterproductive effect on ICI efficacy, which has been reported. This current paradigm has several limitations. First, the CTCAE grade is based on clinical symptoms, including stool frequency, bleeding, abdominal pain, and fever, rather than more objective markers of disease activity. Second, there are no validated tools to describe and measure endoscopic and histologic disease activity in treatment-induced enteropathy, and biopsies are occasionally taken for diagnosis and management because clinical symptoms may not fully reflect the severity of colitis and thus do not allow for a satisfactory assessment of the risk of rupture. Third, there is limited evidence on which to base treatment decisions, either for the prevention or treatment of ICI-induced enteritis. Clinically relevant questions regarding the optimal timing, sequence, and duration of treatment remain unanswered. Finally, with the exception of infliximab, it is unclear what role established systemic therapies for inflammatory bowel disease (IBD, including ulcerative colitis and Crohn's disease) play in the control of ICI-induced colitis.

[0006] In this regard, although some of the histological features of ICI-induced enteritis are the same as those observed in acute colitis such as IBD, the two are immunologically and histopathologically distinct. In particular, we observed increased colonic fibrosis and epithelial ulceration associated with ICI-induced colitis, which is not necessarily closely related to the traditional clinical signs associated with colitis in the traditional view. It has also been reported that the pathogenesis of ICI-induced colitis is mainly driven by T cells, while humoral (B cell) immunity has been shown to be more important in IBD (see, for example, Yanai et al., Clin. Gastroenterol. Hepatol. 2017, 15: e8081; and Bertha et al., ACG Case Rep. J. 2017; 4 th 112). In addition, different forms of acute colitis appear to differ clinically, for example in terms of severity and the potential for rapid progression of complications. In addition, it is unclear whether the chronic colitis observed in patients after ICI treatment ends resembles long-standing IBD colitis disease (Hsieh et al., BMJ Case Rep. 2016, bcr-2016-216641).

[0007] Another common therapy-induced enteropathy is radiation-induced enteropathy. Intestinal radiation toxicity (radiation enteropathy) is typically classified as early (acute) or late (chronic), with the former occurring within 3 months of radiation therapy and the latter occurring more than 3 months after radiation therapy. Although the incidence of severe (grade 3 to 4) late intestinal radiation toxicity has decreased over time, primarily due to improvements in radiation therapy planning and radiation delivery techniques, it has been reported that approximately half of patients who receive radiation therapy will develop some form of chronic gastrointestinal dysfunction. Late radiation enteropathy is a chronic condition that is usually progressive and is associated with significant long-term morbidity.

[0008] As mentioned above, the development of ICI-induced enteritis appears to be associated with a better tumor response to ICI treatment. Recent data suggest that remission of ICI-induced enteritis after treatment with the TNF inhibitor infliximab may be associated with a poorer response to immune checkpoint inhibitors, manifested by more rapid cancer progression. Based on this, we speculate that local immunomodulatory therapy of the inflamed colon, without systemic suppression of the immune system that could negatively affect the anticancer effects of ICIs, could provide an appropriate balance between immunosuppression and immune activation. This would be an attractive approach to meet the growing medical need for further or improved treatments for ICI-induced enteropathy, as well as enteropathy induced by radiation or other therapies.

[0009] In WO2016 / 102660, we described the use of genetically modified lactic acid bacteria to express multiple proteins with wound healing activity, in particular CXCL12, CXCL17 and Ym1, to promote wound healing. The effects of the bacterially expressed proteins reported in this document are believed to arise from the immunomodulatory effects of these proteins on local immune cells near the wound. We have now extended this work to the field of intestinal diseases caused by therapy. Summary of the invention

[0010] We propose that lactic acid bacteria (LAB) modified according to the present disclosure to express certain proteins that help promote inflammation resolution and / or wound healing can be used to treat therapy-induced enteropathy.

[0011] The differences between ICI-induced colitis and IBD-associated colitis described above, as well as the strong requirement for local immunosuppression in ICI-induced colitis, suggest that IBD therapies may be ineffective or inappropriate for ICI-induced colitis. Nevertheless, we remain convinced that the effects of inflammation resolution and wound healing proteins expressed by LAB on local B cells, T follicular helper cells, macrophages, and other immune cells in areas of local immune cell enrichment and in areas of intestinal damage caused by ICI or other therapies would be beneficial in alleviating and treating such damage. We tested this proposal and showed that administration of modified LAB to animal cancer models of colitis and / or ICI therapy was beneficial in reducing disease activity, crypt damage, and epithelial sloughing (erosion and ulceration of the crypt epithelium) in the colon when assessed blindly using conventional histopathology. In addition, modified LAB was also effective in reducing colon shortening caused by ICI therapy. Surprisingly, the beneficial effects of treatment with modified LAB on overt disease were also observed during ICI therapy, so this was not simply an effect of hindering disease progression. More specifically, the study showed that overt signs of injury to the gastrointestinal tract could be treated, demonstrating that the LABs can be administered after the injury caused by the therapy has occurred. Importantly, the beneficial effects of the modified LABs were not observed when the corresponding unmodified LABs (i.e., wild-type bacteria that have not been modified to express the wound healing proteins) were administered.

[0012] Thus, in a broad first aspect, we provide herein engineered lactic acid bacteria (LAB) for use in treating or preventing therapy-induced bowel disease in a subject, wherein the lactic acid bacteria are engineered to express a protein that promotes resolution of inflammation and / or wound healing.

[0013] In particular, engineered LABs are used to treat therapy-induced enteropathy.

[0014] In a specific embodiment, the therapy-induced enteropathy is tumor therapy-induced enteropathy, more specifically enteropathy caused by ICI therapy or radiation therapy.

[0015] The subject is a human or animal subject.

[0016] In particular, the protein is a mammalian protein, more particularly an immunomodulatory protein. In one embodiment, the protein modulates the growth and / or activity of immune cells, particularly macrophages or their precursors. In one embodiment, the protein is a cytokine or chemokine. In one embodiment, the protein is a CXC protein.

[0017] In a more specific embodiment, the protein is selected from CXCL12, CXCL17 and Ym1, in particular CXCL12 or CXCL17. In another embodiment, the protein is TGF-β.

[0018] The LAB may be of any genus, species or strain, but as further described below, the LAB is in particular a Lactobacilli. In one embodiment, the LAB is Limosilactobacillus reuteri (formerly known as Lactobacillus reuteri).

[0019] In another related aspect, provided herein is a pharmaceutical composition comprising engineered lactic acid bacteria (LAB) for treating or preventing therapy-induced enteropathy in a subject, wherein the lactic acid bacteria are engineered to express a protein that promotes resolution of inflammation and / or wound healing.

[0020] In yet another aspect, a use of an engineered lactic acid bacterium (LAB) in the preparation of a medicament for treating or preventing therapy-induced enteropathy in a subject is provided, wherein the lactic acid bacterium is engineered to express a protein that promotes resolution of inflammation and / or wound healing.

[0021] In yet another aspect, a method of treating or preventing therapy-induced enteropathy is provided, the method comprising administering to a subject who has received or is receiving enteropathy-inducing therapy an engineered lactic acid bacteria (LAB) engineered to express a protein that promotes wound healing. DETAILED DESCRIPTION

[0022] The medical uses and methods herein relate to the treatment or prevention of therapy-induced intestinal disorders, in particular the treatment thereof.

[0023] The therapy that causes intestinal disease is not limited and can be any therapy that causes or leads to intestinal disease in a subject when administered to a human or animal subject. However, the therapy is particularly a therapy for cancer, in other words, a tumor therapy. Therefore, in one embodiment, the subject suffers from or has been diagnosed with cancer (i.e., is a cancer patient).

[0024] Cancer is not limited and can be any cancer. Specifically, cancer can be a cancer suitable for or susceptible to immune checkpoint inhibitors (ICI) treatment. For example, cancer can be melanoma, urothelial cell carcinoma, renal cell carcinoma or lung cancer (such as non-small cell lung cancer), but these are only representative examples. The characteristics of cancer can be solid tumors. In one embodiment, cancer can be advanced cancer. The nature of cancer is not critical for the proposed use. Therefore, cancer can be cancer of any organ or tissue in the body. However, in one embodiment, cancer does not include (or cancer is not) colorectal cancer.

[0025] The induction therapy of enteropathy may be therapy using any therapeutic agent (including pharmacological or pharmaceutical agents), including immunotherapy (such as immunotherapeutic agents) or radiation therapy. Thus, the therapy may involve administering radiation or a small molecule drug, such as a chemotherapeutic agent or a biomolecule, such as a protein, for example an antibody, or an antibody-derived or antibody-based protein to the subject.

[0026] In one embodiment, the therapy-induced enteropathy is immune checkpoint inhibitor (ICI)-induced enteropathy or radiation-induced enteropathy (which term is synonymous with "radiation enteropathy"). In a more specific embodiment, the radiation-induced enteropathy is delayed radiation-induced enteropathy.

[0027] The term "enteropathies" is used broadly herein to include any injury, damage or inflammation of the intestinal tract or in other words the gastrointestinal tract, especially the lower gastrointestinal tract, in particular the small intestine and the large intestine. It may include any histological changes in the gastrointestinal tract compared to a healthy individual before treatment or not receiving enteropathy inducing therapy. More specifically, these histological changes may be histopathological changes.

[0028] The histological features of the enteropathy caused by therapy include crypt inflammation, intraepithelial neutrophil lymphocytes, glandular destruction, mucosal surface erosion (such as mucosal ulcers), crypt abscesses, apoptosis and necrosis. Other symptoms include diffuse erythema, edema, vascular loss, hemodynamic instability, severe congestion, intestinal ischemia and perforation. In general, inflammatory changes may occur in the lesions of the intestine, and the size of the lesions may be different. Therefore, the enteropathy to be treated herein can be defined as inflammation or inflammatory changes in the gastrointestinal tract, especially in the intestine. Inflammatory changes may occur before obvious inflammation, and may be found before or after dominant inflammation is detected. These changes may cause the colon to shorten or the colon to increase in weight. As described above, the severity of the enteropathy caused by therapy can be graded (1 to 4 grades, with increasing severity) according to the Common Terminology Criteria for Adverse Events (CTCAE). In general, enteropathy can be manifested as colitis, i.e. inflammation of the colon. However, the term "intestinal disease" includes lower grade damage or inflammatory changes, including those that do not yet manifest as overt colitis in traditional clinical assessments. In a specific embodiment, the intestinal disease caused by the therapy to be treated herein may be characterized by crypt damage, epithelial sloughing, and / or shortening or increased weight of the colon.

[0029] Furthermore, in some cases, therapy-induced enteropathy is alternatively or additionally characterized by intestinal fibrosis. As described above, we recently observed that fibrosis and edema may occur in mouse models of ICI-induced enteropathy, while clinical signs of more traditional colitis or overt colitis are not measurable or not yet found. The colon shortening observed in these ICI-induced colitis studies was greater than 20%, which is comparable to the most severe grades of colitis in other models, such as chemically induced colitis using dextran sulfate sodium (DSS), which is primarily manifested by clinical signs such as weight loss, diarrhea, and blood in the stool.

[0030] Common markers used to determine or assess inflammatory bowel disease (IBD) or colitis disease activity can be used to assess therapy-induced enteropathy. Thus, therapy-induced enteropathy can also be detected and / or diagnosed, at least in part, by detecting inflammatory markers, including, for example, the presence or activity of proinflammatory cytokines, calprotectin, and / or immune cells (including T cells in the intestine, etc.).

[0031] Clinical signs of enteropathy include abdominal pain, increased number of bowel movements per day, diarrhea, rectal bleeding, and mucus in the stool. These clinical symptoms may interfere with activities of daily living. As the severity increases, by stage 4, symptoms may include hemodynamic instability, severe congestion, intestinal ischemia, perforation, megacolon, and sepsis. Death may eventually occur.

[0032] The enteropathy caused by therapy can be diagnosed based on one or more clinical symptoms (particularly diarrhea) and the measurement results of serum inflammatory markers and electrolytes. Significant abnormalities of enteropathy caused by therapy include anemia, elevated C-reactive protein levels, and reduced serum albumin levels. It can be confirmed by endoscopy or proctoscopy and / or biopsy. Interestingly, mouse models have shown that enteropathy caused by ICI does not necessarily show clinical features common in other types of enteropathy and IBD, such as weight loss, diarrhea, and blood in the stool, but rather shows clinical features such as increased fibrosis development and epithelial ulcers, particularly in the colon (Examples 3 and 4). Therefore, increased fibrosis can also be evaluated as a clinical marker for enteropathy caused by therapy. Fibrosis may lead to shortening of the colon, which can be considered an indicator of colon fibrosis.

[0033] Common clinical features of radiation-induced enteropathy include changes in intestinal transport function, malabsorption and impaired mobility, and severe cases may develop into intestinal obstruction, fistula formation or obvious intestinal perforation. Therefore, the medical use herein includes the treatment of dominant or obvious clinical diseases or preclinical conditions. That is, the enteropathy to be treated includes obvious or dominant diseases, such as diarrhea or colitis symptoms shown by clinical symptoms, and preclinical enteropathy, that is, clinical symptoms have not yet appeared, but the intestine has been damaged, which is determined by histological characteristics or changes, as described above, especially including fibrosis and epithelial ulcers, especially in the colon. Therefore, enteropathy can be diagnosed by dominant symptoms and / or gastrointestinal examinations (such as histological examinations, biopsies or endoscopic examinations).

[0034] The medical uses herein include treating a confirmed disease, for example, administering an engineered LAB after discovery or diagnosis of therapy-induced enteropathy in a subject, which represents a particularly advantageous aspect of the therapy disclosed herein. Specifically, the therapy herein relates to treating therapy-induced colitis after colitis is manifested. However, LAB can also be used for prevention, i.e., delaying or preventing the development of therapy-induced enteropathy. In this case, LAB can be administered to the subject at the beginning of treatment, before enteropathy occurs or before diagnosis, for example, before dominant or obvious colitis occurs. For example, LAB can be administered together with therapy, or shortly after therapy. In this case, LAB can be used to prevent the development of colitis.

[0035] In one embodiment, the engineered LABs can be used to treat subjects who are undergoing therapy for which the intestine (particularly the colon) exhibits or is at risk of (ie, due to) increased fibrosis and / or epithelial ulceration.

[0036] In another embodiment, engineered LABs can be used to inhibit the development of intestinal (especially colonic) fibrosis and / or epithelial ulcers in subjects who are receiving therapy. The therapy may be any therapy described herein, and may also be referred to as intestinal disease-inducing therapy. The term "inhibition" as used herein includes any effect that limits fibrosis and / or epithelial ulcers, such as reducing, preventing and / or delaying fibrosis and / or epithelial ulcers. Therefore, the subject may be a subject with a potential risk of intestinal disease caused by therapy.

[0037] In another embodiment, the subject presents or is classified as greater than or equal to grade 2 therapy-induced colitis according to the CTCAE.

[0038] In another embodiment, the engineered LAB can be used to restore or maintain the severity of therapy-induced colitis to less than or equal to grade 2 according to the CTCAE.

[0039] In one embodiment, the therapy-induced enteropathy is steroid-refractory enteropathy, in particular steroid-refractory ICI-induced enteropathy. However, in another embodiment, the subject is not using steroids. In yet another embodiment, the subject is not using steroids and exhibits grade 1 to 2 therapy-induced colitis according to CTCAE.

[0040] In another embodiment, the engineered LAB is administered or used (or intended for use) in combination with a steroid.

[0041] ICI therapy may be a therapy using any immune checkpoint inhibitor. Immune checkpoint inhibitors are broadly defined as any agent that inhibits the activity or function of a checkpoint protein. The agent may be an agent that binds to a checkpoint protein or a checkpoint protein receptor. Therefore, a checkpoint inhibitor may be a binder for a checkpoint protein or its receptor. The binder may be an antibody, or may be based on an antibody or derived from an antibody. The antibody may be a natural antibody or a synthetic antibody, or a fragment or derivative thereof. The three main immune checkpoints currently targeted by ICI are PDL-1, PD-L1 (PD-L1 is programmed cell death ligand 1, PD-1 is a receptor for PD-L1) and CTLA-4 (cytotoxic T lymphocyte antigen 4), but the medical uses and methods herein are not limited to these, and include targeting any immune checkpoint.

[0042] Other checkpoint proteins include CD-137 (4-1BB), a co-stimulatory checkpoint protein; lymphocyte activation gene 3 (LAG-3, CD223), a CD4-related inhibitory receptor co-expressed with PD-1 on tolerogenic T cells; the B7 superfamily proteins B7-H3 and B7-H4; the T-cell protein TIM3; and phosphatidylserine (PS), a phospholipid in normal cells that is transferred to the extracellular surface during apoptosis, thereby inhibiting excessive immune activation that may occur during the processing and clearance of decaying cellular material.

[0043] Examples of checkpoint inhibitors include: Tremelimumab (CP-675206), a human IgG2 monoclonal antibody with high affinity for CTLA-4; Ipilimumab (MDX-010), a human IgG1 monoclonal antibody with high affinity for CTLA-4; Nivolumab (BMS-936558), a human monoclonal anti-PD-1 IgG4 antibody that essentially lacks detectable antibody-dependent cellular cytotoxicity (ADCC); MK-3475 (formerly Lambrolizumab), a human The drugs include: a human IgG4 anti-PD-1 antibody containing a mutation at C228P designed to prevent Fc-mediated ADCC; urelumab (BMS-663513), a fully human IgG4 monoclonal anti-CD137 antibody; an anti-LAG-3 monoclonal antibody (BMS-986016); bavituximab (chimeric 3G4), a chimeric IgG3 antibody against PS; MPDL3280A (RG7446), a human IgG1-kappa anti-PD-L1 monoclonal antibody; and MEDI4736, another IgG1-kappa PD-L1 inhibitor.

[0044] Another alternative approach is to use B7-DC-Fc fusion protein to competitively block the PD-1 receptor, so such fusion proteins can also be used.

[0045] Therefore, in one embodiment, the immune checkpoint inhibitor is an antibody against PDL-1, PD-1, CTLA4, TIM3, CD137, CD223, PS or KIR on NK cells, or is a B7-DC-Fc fusion protein.

[0046] LAB used herein is engineered to express wound healing and / or anti-inflammatory proteins. One or more wound healing and / or anti-inflammatory proteins can be expressed. The term "engineering" refers to that LAB is modified to express proteins, more specifically genetically modified. Therefore, the term "engineering" is synonymous with "modification" or "genetic modification", and can be used interchangeably with "modification" or "genetic modification". In other words, engineered LAB is a LAB into which one or more nucleic acid molecules have been introduced, and the nucleic acid molecule comprises a nucleotide sequence encoding a protein. Therefore, the nucleic acid molecule introduced encodes a protein that is heterologous (i.e., non-naturally expressed) to LAB. The term "nucleotide sequence" used herein is synonymous with "gene" or "gene sequence" and can be used interchangeably, referring to a sequence encoding a related protein. Specifically, the term "gene" used herein does not mean or require the presence of any promoter sequence or other expression control sequence in the coding sequence. Therefore, the term "gene" does not mean or require the presence of a native promoter or other control sequence of a native gene, but is only a coding sequence encoding the protein.

[0047] The nucleic acid molecule can be introduced into the LAB in the form of an autonomously replicating element (e.g., a plasmid or other vector described further below) or as part of an autonomously replicating element, or the nucleic acid molecule can be integrated into the chromosome of a recipient or host LAB. Thus, the nucleotide sequence encoding the protein can be present in an engineered LAB integrated into the host genome, or it can be present in a vector of an engineered LAB independent of the host genome.

[0048] Wound healing proteins can be any protein that promotes wound healing. Similarly, anti-inflammatory proteins can be any protein that promotes or helps anti-inflammatory effects. In other words, anti-inflammatory proteins can be called "anti-inflammatory" proteins. Specifically, wound healing and / or anti-inflammatory proteins are mammalian proteins. Wound healing and / or anti-inflammatory proteins can advantageously be immunomodulatory proteins, i.e., proteins that regulate the activity of immune cells. Therefore, in one embodiment, wound healing and / or anti-inflammatory proteins can be defined as immunoactive proteins, especially immunoactive proteins that have local activity on immune cells present near wounds (here, enteropathy), i.e., immunoactive proteins that are locally located in the intestines of subjects. In a specific embodiment, the protein is an anti-inflammatory protein or a protein with anti-inflammatory activity. Specifically, the protein can stimulate the growth and / or activity of immune cells, especially immune cells present in the intestines, especially macrophages. The protein can promote or enhance the anti-inflammatory effect of immune cells (such as macrophages). The protein can stimulate the proliferation of local macrophages and / or other immune cells, and can induce phenotypes to change to anti-inflammatory phenotypes. Alternatively or additionally, the protein may have an anti-fibrotic effect, ie may be an anti-fibrotic protein.

[0049] The wound healing and / or anti-inflammatory protein may have a palliative effect, i.e., improve or reduce one or more clinical signs or symptoms or histological features of intestinal diseases caused by the therapy as described above. Specifically, the protein may reverse disease progression, thus, for example, the protein may reduce crypt damage and epithelial sloughing or intestinal cell apoptosis, e.g., as determined by histological methods, to reduce inflammatory markers, reduce colon shortening, etc., or reduce any marker of disease activity. The protein may further inhibit (i.e., prevent or reduce) the development of gastrointestinal tract, especially intestinal fibrosis.

[0050] The protein may be a cytokine, such as an interleukin, a chemokine or a growth factor. It may be a CXC protein. In one embodiment, the protein is selected from one or more of CXCL12, CXCL17, Ym1, TGF-β, IL-22, IL-27, IL-4, IL-10, IL-12, IL-8 or SP1. In a more specific embodiment, the protein is selected from one or more of CXCL12, CXCL17, Ym1 or TGF-β.

[0051] CXCL12 (also known as SDF-1; SEQ ID NOs: 3 and 6) is constitutively expressed in tissues and acts through the receptor CXCR4 present on leukocytes and endothelial cells to induce a variety of cellular behaviors. CXCL12 is found at high levels in macrophages that specialize in tissue remodeling.

[0052] CXCL17 (SEQ ID NOs: 9 and 12) was originally classified as a chemokine with effects on tissue macrophage phenotypes similar to those of CXCL12. Similar to CXCL12, CXCL17 is co-regulated with VEGF-A measured in cell culture. CXCL17 is primarily found in mucosal tissues and is reported to have direct antimicrobial effects against pathogenic bacteria also present on the skin, while having no effect on the survival of Lactobacillus casei. In addition to its antimicrobial effects, CXCL17 is reported to have microbial and antifibrotic effects as well as chemotactic properties. Recently, the classification of CXCL17 as a chemokine has been questioned, but this is not relevant to its proposed use in this article.

[0053] Another target protein is the chitinase-like protein Ym1 (SEQ ID NOs: 15 and 18). Chitin is a common polysaccharide in bacterial biofilms. Ym1 can both hinder the formation of biofilms and induce macrophage functions that are very important for tissue remodeling and wound healing. It is specific to macrophages because it is not absorbed by vascular cells or epithelial cells.

[0054] Another target protein is TGF-β. TGF-β exists in three different isoforms, TGF-β1, TGF-β2, and TGF-β3, all of which are included in this article. TGF-β is a multifunctional cytokine that is secreted by a variety of cell types, including macrophages, and plays a role in regulating inflammatory processes, including those in the intestine.

[0055] More specifically, the protein can be mouse CXCL12, in particular mouse CXCL12-1α (SEQ ID NO: 3); human CXCL12, in particular human CXCL12-1α (SEQ ID NO: 6); mouse CXCL17 (SEQ ID NO: 9); human CXCL17 (SEQ ID NO: 12); mouse Ym1 (SEQ ID NO: 15); human Ym1 (SEQ ID NO: 18); and human TGF-β (SEQ ID NO: 27).

[0056] In one embodiment, the protein is selected from the group consisting of mouse CXCL12-1α having an amino acid sequence as shown in SEQ ID NO: 3 or 2, or an amino acid sequence having at least 80% sequence identity thereto; human CXCL12-1α having an amino acid sequence as shown in SEQ ID NO: 6 or 5, or an amino acid sequence having at least 80% sequence identity thereto; mouse CXCL17 having an amino acid sequence as shown in SEQ ID NO: 9 or 8, or an amino acid sequence having at least 80% sequence identity thereto; human CXCL17 having an amino acid sequence as shown in SEQ ID NO: 12 or 11, or an amino acid sequence having at least 80% sequence identity thereto; mouse Ym1 having an amino acid sequence as shown in SEQ ID NO: 15 or 14, or an amino acid sequence having at least 80% sequence identity thereto; human Ym1 having an amino acid sequence as shown in SEQ ID NO: 18 or 17, or an amino acid sequence having at least 80% sequence identity thereto; and human TGF-β having an amino acid sequence as shown in SEQ ID NO: 27, or an amino acid sequence having at least 80% sequence identity thereto.

[0057] Can prepare the nucleic acid molecule that comprises the nucleotide sequence of coding protein as defined above or described.Nucleic acid molecule can provide in the form of recombinant construct, and this recombinant construct comprises the encoding nucleotide sequence that is operably connected to one or more expression control sequences (for example promoter), optionally comprises one or more other regulating sequences.Each encoding sequence can be controlled by independent expression control sequence, but for convenience, all encoding sequences to be introduced can be controlled by identical expression control sequence.The construct that is composed of the nucleic acid molecule that comprises one or more encoding sequences and one or more expression control sequences can be referred to as expression construct in this article.

[0058] Nucleic acid molecules or recombinant constructs can be contained in a vector, such as for the purpose of cloning or expression, for example, in an expression vector. The term "vector" as used herein refers to any genetic element that can serve as a vector for genetic transfer, expression or replication of an exogenous nucleic acid sequence in a host strain. The vector can exist as a single nucleic acid molecule or as two or more independent nucleic acid molecules. When present in a host LAB, the vector can be a single copy vector or a multicopy vector.

[0059] The specific vector used herein is an expression vector. In such a vector, one or more genes can be inserted into the vector molecule in an appropriate orientation and close to the expression control elements residing in the expression vector molecule so as to direct the expression of one or more proteins when the vector molecule is present in the host LAB.

[0060] The construction of appropriate expression vectors and other recombinant or genetic modification techniques for practicing the methods herein are well known in the art (see, e.g., Green and Sambrook, Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Laboratory Press (Cold Spring Harbor, NY) (2012), and Ausubel et al., Short Protocols in Molecular Biology, Current Protocols John Wiley and Sons (New Jersey) (2002).

[0061] The vector may be a plasmid, a cosmid, a phagemid or other phage vector, a viral vector, an episome, an artificial chromosome (such as a bacterial artificial chromosome (BAC) or a P1 artificial chromosome (PAC)) or other polynucleotide construct, and may, for example, include one or more selectable marker genes and appropriate expression control sequences.

[0062] Generally, regulatory control sequences are operably linked to coding nucleic acid sequences, including constitutive, regulated and inducible promoters, transcription enhancers, transcription terminators, etc., which are well known in the art. As described above, coding nucleic acid sequences can be operably linked to a common expression control sequence or to different expression control sequences.

[0063] In a specific embodiment, the nucleotide sequence is provided in a plasmid. More specifically, the plasmid is used for expressing proteins in milk-acid bacteria, and therefore provides or is adapted to such purposes (for example, the plasmid is designed, selected, adapted to or modified for specificity or specific use in milk-acid bacteria). Therefore, in one embodiment, the plasmid is used for specific expression in the milk-acid bacteria relative to general bacterium or microorganism. Plasmid can be adapted to expression in milk-acid bacteria by regulatory elements (regulatory sequences) and / or encoding sequences (for example, selected or modified for expression in milk-acid bacteria).

[0064] Therefore, the plasmid may comprise one or more regulatory (i.e. expression control) sequences that allow or are specific for expression in lactic acid bacteria. Therefore, the plasmid may contain an expression control sequence that is derived from or is suitable for or is specific for expression in lactic acid bacteria. Suitable expression control sequences include translation (such as start and stop codons, ribosome binding sites) and transcription control elements (such as promoter-operator region, termination stop sequence) that are connected to the nucleotide sequence of the protein to be expressed in the matching reading frame. The regulatory sequence may be operably connected to the nucleotide sequence encoding the protein, thereby driving or controlling the expression of the protein.

[0065] The plasmid may be introduced into the lactic acid bacteria cells by any suitable transformation technique, such techniques being well described in the literature. The bacterial cells may be cultured or otherwise maintained under conditions that allow the plasmid to express the protein. This may include the condition of the subject's gastrointestinal tract.

[0066] In one embodiment, the promoter controlling protein expression in the plasmid is a promoter that allows or is specific for expression in lactic acid bacteria. Therefore, the plasmid may be included in a nucleotide sequence encoding a protein under the control of a promoter that can express protein in lactic acid bacteria (or is operably connected to). In a particularly preferred embodiment, the plasmid comprises a lactic acid bacteria promoter, i.e., the promoter controlling protein expression is a promoter derived from lactic acid bacteria, or more specifically, a gene obtained from or derived from expression in lactic acid bacteria.

[0067] In some embodiments, in addition to the lactobacillus promoter, the plasmid may also include other regulatory elements or sequences obtained from or derived from lactobacillus to control the expression of the protein. Therefore, for example, such other lactobacillus expression control elements or sequences may include enhancers, terminators and / or translation control elements or sequences as described above. In some embodiments, the plasmid may also contain regulatory elements or sequences that control or regulate the expression of the promoter, such as operator sequences or one or more regulatory genes, as further discussed below.

[0068] Alternatively or additionally, the plasmid may be adapted (or modified, etc.) for use in lactic acid bacteria by codon-optimizing the nucleotide sequence encoding the protein for expression in lactic acid bacteria.

[0069] In a preferred embodiment, the promoter used to express the protein is a regulated (regulatable) or inducible promoter. Thus, by providing or contacting the bacteria with a regulatory molecule or inducer that activates or turns on (induces) the promoter, the expression of the protein can be controlled or regulated (e.g., started, such as at a desired or appropriate time). This is advantageous in the case of delivering proteins to intestinal disease sites.

[0070] The expression system for expressing proteins in lactic acid bacteria may comprise: (i) a plasmid comprising a nucleotide sequence encoding a protein under the control of an inducible promoter capable of expressing the protein in lactic acid bacteria; and (ii) an inducing agent (or regulatory molecule) for the promoter. The expression system may conveniently be provided in the form of a kit comprising the above components (i) and (ii).

[0071] Therefore, a particular aspect of the invention provides a pharmaceutical product (such as a kit or a combination product) comprising:

[0072] (i) a lactic acid bacterium comprising a nucleotide sequence encoding the protein under the control of an inducible promoter capable of expressing the protein in the lactic acid bacterium; and

[0073] (ii) an inducer (or regulatory molecule) for a promoter,

[0074] The pharmaceutical products as combined preparations can be used separately, sequentially or simultaneously for the treatment or prevention of therapy-induced enteropathy in a subject.

[0075] In general, in any aspect of this invention, the subject can be any human or animal subject, including, for example, domestic animals, livestock, laboratory animals, competitive animals, or zoo animals. Animals are particularly mammals, but also include other animals, such as birds. Thus, the animal can be a primate, a rodent (such as a mouse or rat), or a horse, dog, or cat. Most preferably, the subject is a human.

[0076] Lactic acid bacteria (LAB) or Lactobacillus (Lactobacillales) are branches of Gram-positive, low GC, acid-resistant, usually non-spore-producing, non-respiratory rod-shaped (bacillus) or spherical (coccus) bacteria with common metabolism and physiological characteristics. These bacteria produce lactic acid as the main metabolic end product of carbohydrate fermentation, which is characterized by increased tolerance to acidity (low pH range). These characteristics of LAB make it superior to other bacteria in natural fermentation, because LAB can withstand the acidity increased by organic acid (such as lactic acid). Therefore, LAB plays an important role in food fermentation, because acidification suppresses the growth of corrupt substances. Some LAB strains also produce protein bacteriocins, which further suppress the corruption and growth of pathogenic microorganisms. LAB has a generally recognized safe (GRAS) status and is one of the most important microbial groups adopted in the food industry.

[0077] The core genera comprising the lactic acid bacteria group are Lactobacillus*, Leuconostoc, Pediococcus, Lactococcus, Enterococcus, Weissella and Streptococcus, as well as the more marginal Aerococcus, Carnobacterium, Enterococcus, Oenococcus, Sporolactobacillus, Tetragenococcus and Vagococcus. Any lactic acid bacteria of these genera can be used for the methods described herein, particularly bacteria of the genus Lactobacillus or Lactococcus, especially bacteria of the genus Lactobacillus. (Lactobacillus, Pediococcus, Weissella and Leuconostoc have recently been unified, but are also divided into 25 genera together. For simplicity, this article uses the old classification. Reference: Zheng, J., Wittouck, S., Salvetti, E., Franz, CMAP, Harris, HMB, Mattarelli, P. et al. (2020). Ataxonomic note on the genus Lactobacillus: Description of 23 novel genes, amended description of the genus Lactobacillus Beijerinck 1901, and union of Lactobacillaceae and Leuconostocaceae. International Journal of Systematic and Evolutionary Microbiology, 70(4), 2782–2858. http: / / doi.org / 10.1099 / ijsem.0.004107).

[0078] In one embodiment, the LAB is a lactobacillus. This may include any species of lactobacillus, many of which are known and many of which have been deposited and are publicly available from culture collections. More specifically, the lactobacillus is Lactobacillus reuteri. This species has recently been reclassified as Lactobacillus mucilaginosus. Thus, the term "lactobacillus" as used herein includes Limosilactobacillus (or in other words, in one embodiment, the LAB is a lactobacillus or Lactobacillus mucilaginosus).

[0079] Lactobacillus reuteri may be any strain, many of which are known in the art and have been reported. Many strains of Lactobacillus reuteri are publicly available from culture collections, such as Lactobacillus reuteri DSM20016 or Lactobacillus reuteri ATCC PTA 6475. Of particular note is the Lactobacillus reuteri R2LC strain.

[0080] Lactobacillus reuteri R2LC has been reported in the literature and is available from Professor Siv Ahnré of Lund University, Sweden (see Ahnre et al., Nutrients 2011, 3, 104-117). The Lactobacillus reuteri R2LC strain was deposited at the Culture Collection of the University of Gothenburg (CCUG) in December 2021 with the initial accession number R2LC20211221. The Lactobacillus reuteri R2LC strain was deposited at the Leibniz Institute DSMZ-German Collection of Microorganisms and Cell Cultures (7B, D-38124, Brunswick, Germany) on August 26, 2022 in accordance with the Budapest Treaty with the accession number DSM 34372.

[0081] As described above, LAB may contain or express one or more of the proteins. Therefore, LAB may contain or express a combination of two or more of any of the proteins listed above, such as a combination of CXCL12, CXCL17, Ym1 and / or TGF-β proteins (such as two or more of CXCL12, CXCL17, Ym1 or TGF-β). Alternatively, LAB may contain or express two or more types of CXCL12, CXCL17, Yml and / or TGF-β proteins, or any other protein listed or mentioned above (such as mouse and human CXCL12, etc.). When expressing more than one protein, the protein may be expressed by a nucleotide sequence encoding the protein under the control of a single promoter, or more than one promoter may be used. For example, each protein may be expressed by a separate promoter, which may be the same or different. The technology for expressing two or more proteins together by the same plasmid is well known in the art, including, for example, translation coupling technology, and the method for achieving this is known and available in the art. For example, the use of P2A and T2A sequences allows for the simultaneous expression of multiple transgenes under one promoter.

[0082] Proteins can be native or natural proteins (i.e., nucleotide sequences can encode proteins with naturally occurring amino acid sequences), and can be from any species in which these proteins exist. In general, proteins are mammalian proteins, and as described above, human and mouse proteins are preferred. However, native nucleotide sequences or protein sequences can be modified, for example, by one or more amino acid additions, insertions, deletions and / or substitutions, as long as the function or activity of the protein is not substantially or significantly changed, for example, as long as the activity of the protein is substantially retained. Proteins can be fragments or truncated variants of natural proteins. For example, sequence-modified variant proteins can show at least 80%, 85%, 90% or 95% of the activity of the parent protein from which it is derived. This can be evaluated according to tests of related protein activity known in the art. For example, activity can be measured in a receptor phosphorylation or calcium flux system after connection in cultured cells treated with proteins, or in a system of in vitro or in vivo cell chemotaxis in which cells are recruited to a model of infected proteins. In vitro assays based on chemotaxis are described in Nesmelova et al., JBC Papers in Press, June 12, 2008, DOI 10.1074 / jbc.M803308200 or Massena et al., Blood. 2015 Oct 22; 126(17): 2016-26. doi: 10.1182 / blood-2015-03-631572. Epub 2015 Aug 18. Hatse et al., Cytometry A. 2004 Oct; 61(2): 178-88 describe additional in vitro chemokine activity assays that may be employed. The terms "CXCL12", "CXCL17", "Ym1" or "TGF-β" or any other protein name or abbreviation mentioned above include not only the native protein, but also functionally equivalent variants or derivatives thereof. Thus, the protein may be a synthetic or sequence-modified variant, and may also contain one or more other modifications, such as post-translational modifications, etc.

[0083] As described above, the encoded protein may have the amino acid sequence of the above-mentioned natural human or mouse protein, i.e., SEQ ID NO: 3 and 6 (mouse and human CXCL12, respectively), SEQ ID NO: 9 and 12 (mouse and human CXCL17, respectively), SEQ ID NO: 15 and 18 (mouse and human Ym1, respectively) or SEQ ID NO: 27 (human TGF-β), or an amino acid sequence having at least 80% sequence identity with any of the above sequences. Advantageously, as described above, the nucleotide sequences encoding these natural proteins may be codon-optimized for expression in lactic acid bacteria. This may result in changes in the amino acid sequence of the encoded protein. For example, the codon-optimized sequence may encode a sequence such as a secretory sequence suitable for (or more suitable for) lactic acid bacteria. Therefore, compared to the natural protein, the "optimized" protein encoded by the codon-optimized nucleotide sequence may include an altered or substituted leader sequence or signal sequence (such as a secretory sequence). In a preferred embodiment, the mature or cleavage form of the protein encoded by the codon-optimized sequence is the same as the natural protein. The protein encoded by the codon-optimized nucleotide sequence may have an amino acid sequence as shown in SEQ ID NO: 2, 5, 8, 11, 14 or 17. Thus, the protein encoded by the plasmid may have an amino acid sequence as shown in SEQ ID NO: 2 and 5 (mouse and human CXCL12, respectively), SEQ ID NO: 8 and 11 (mouse and human CXCL17, respectively) and SEQ ID NO: 14 and 17 (mouse and human Ym1, respectively), or an amino acid sequence having at least 80% sequence identity to any of the above sequences.

[0084] In other embodiments, the encoded protein may have an amino acid sequence having at least 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity to any of the above amino acid sequences.

[0085] Sequence identity can be easily determined by methods and software known in the art and readily available. Therefore, sequence identity can be assessed by any convenient method. However, in order to determine the degree of sequence identity between sequences, it is useful to perform a computer program for multiple sequence alignments, such as Clustal W (Thompson et al., 1994) Nucleic Acids Res., 22: 4673-4680.

[0086] Programs that compare and align paired sequences, such as ALIGN (Myers and Miller (1988) CABIOS, 4: 11-1), FASTA (Pearson and DJ Lipman 1988 PNAS, 85: 2444-2448; and Pearson (1990), Methods Enzymol., 183: 63-7), BLAST, and GAP BLAST (Altschul et al. (1997). Nucleic Acids Res., 25: 3389-3402) can also be used for this purpose and can be used with default settings. In addition, the Dali server of the European Bioinformatics Institute provides structure-based protein sequence alignments. Multiple sequence alignments and percentage identity calculations can be determined using standard BLAST parameters (e.g., using sequences from all available organisms, matrix Blosum 62, gap scoring: Existence 11, extension 1). Alternatively, the following programs and parameters may be used: Program: Align Plus4, Version 4.10 (SciEd Central Clone Manager Professional Suite). DNA comparison: global comparison, standard linear scoring matrix, mismatch penalty = 2, open gap penalty = 4, extension gap penalty = 1. Amino acid comparison: global comparison, BLOSUM 62 scoring matrix.

[0087] Variants of a naturally occurring polypeptide sequence as defined herein may be generated synthetically, for example by employing standard molecular biology techniques known in the art, for example standard mutagenesis techniques, such as site-directed or random mutagenesis (eg using gene shuffling or error-prone PCR).

[0088] Derivatives of the proteins defined herein may also be encoded. A derivative is a protein as described above or a variant thereof, wherein the amino acids have been chemically modified, for example by glycosylation or the like.

[0089] When a protein comprises an amino acid substitution relative to the sequence of a native protein, the substitution may preferably be a conservative substitution. The term "conservative amino acid substitution" refers to any amino acid substitution in which an amino acid is replaced (substituted) by an amino acid of similar physicochemical properties (i.e., the same class / group of amino acids). For example, small residues glycine (G), alanine (A), serine (S) or threonine (T); hydrophobic or aliphatic residues leucine (L), isoleucine (I), valine (V) or methionine (M); hydrophilic residues asparagine (N) and glutamine (Q); acidic residues aspartic acid (D) and glutamic acid (E); positively charged (basic) residues arginine (R), lysine (K) or histidine (H); or aromatic residues phenylalanine (F), tyrosine (Y) and tryptophan (W) can be interchangeably substituted without substantially changing the function or activity of the protein.

[0090] As mentioned above, it is advantageous to use an inducible promoter to express a protein. "Inducible" refers to any promoter whose function (i.e., the activity or action that allows or causes transcription of a coding nucleotide sequence) can be regulated or controlled. Therefore, the term "inducible" is a synonym and can be used interchangeably with "regulatable" (or "regulatory"). Therefore, there is no constitutive expression of a protein. Therefore, the expression of a protein can be induced or turned on (or more specifically turned on and off). More specifically, expression can be induced or turned on for a limited or defined time. This may be because expression stops after a period of time, and / or because the bacterial cell dies.

[0091] In some embodiments, a promoter may not be expressed (transcribed) until the promoter is induced (or alternatively referred to as activated). However, as with any biological system, the lack of activity may not be absolute, and there may be some basal promoter activity in the absence of promoter activation or induction. However, in preferred embodiments, any basal expression of an uninduced promoter is low, minimal or insignificant, or more preferably trace or negligible. Therefore, when the promoter is induced, the expression of an inducible promoter is advantageously measurable or significantly increased compared to when the promoter is not induced.

[0092] Inducible promoters are well known in the art, including those for use in lactic acid bacteria, and any suitable inducible promoter suitable for expression in lactic acid bacteria may be used.

[0093] Inducible promoter can be induced (or activated) in the presence of an inducer or activator molecule, which can act on the promoter directly or indirectly, and can add an inducer or activator molecule to induce promoter, or more generally cause or realize promoter induction or activation, and allow the expression of protein, or can induce (or activate) by changing the conditions of the bacterium containing plasmid, such as by changing the conditions of lactic acid bacteria, such as starvation or consumption of specific nutrients. The inducing agent of promoter can be encoded by a regulatory gene, and in one embodiment, the regulatory gene itself can be induced or activated. Therefore, the term "inducer" is widely used in this article, including any regulatory molecule, or in fact any permissive condition, which can activate or start an inducible promoter, or allow or cause an inducible promoter to be induced. Therefore, the induction of an inducible promoter can include introducing (such as contacting lactic acid bacteria containing plasmid) regulatory molecules or allowing the conditions of promoter induction (activation). In some embodiments, the inducing agent can be an activating peptide. This can act directly or indirectly to induce promoter, such as further described below.

[0094] As mentioned above, the promoter obtained from or derived from milk-acid bacteria is particularly suitable. These promoters can be natural promoters or modified or mutated promoters. For example, suitable promoters can be identified by culturing milk-acid bacteria in a wound and by determining which genes are expressed or up-regulated in the bacteria in the wound. The promoters from these genes can then be identified. Alternatively, many different promoters and expression systems in or for milk-acid bacteria have been identified and described, or are available in the art, including expression plasmids containing such promoters or expression systems for LAB. Any such known plasmid or expression system can be used as the basis for recombinant plasmids of the present invention.

[0095] A variety of inducible expression systems are known in the art for use with LABs such as Lactobacillus. One example includes An autoinduction system for the manganese starvation-inducible promoter of the manganese transporter of Lactobacillus plantarum NC8 described by et al. in FEMS Microbiol Lett 342 (2013) 37-44.

[0096] This system does not require the addition of external inducers to produce recombinant proteins.

[0097] Duong et al., Microbial Biotechnology (2010) 4(3), 357-367, describe expression vectors for lactobacilli based on the broad-range pWV01 replicon and containing promoters from operons involved in fructooligosaccharide (FOS), lactose or trehalose metabolism or transport or glycolysis. Such promoters are inducible by their specific carbohydrates and repressed by glucose.

[0098] More specifically, the inducible expression system may comprise an inducible promoter involved in the production of LAB proteins, particularly bacteriocins. The activity of such promoters may be controlled by a homologous regulatory system based on a bacteriocin regulator, such as a two-component regulatory (signal transduction) system, which responds to an externally added activation peptide (i.e., an inducer / regulatory molecule in the form of a peptide) and genes encoding histidine protein kinases and response regulators, which are necessary for the activation of the promoter after induction by the activation peptide.

[0099] In one embodiment, the expression system can be based on the Nisin Controlled Expression (NICE) system, based on a combination of the nisA promoter and the nisRK regulatory gene. This system is based on the promoter and regulatory genes from the nisin gene cluster of Lactococcus lactis and has been used to develop regulated gene expression systems for Lactococci, Lactobacillus and other Gram-positive bacteria (in et al., FEMS Microbiol Lett. 2003; 229(1): 119-126 and et al., Microbiology. 2005 Jul; 151(Pt 7): 2439-49).

[0100] Although NICE systems are efficient and well-regulated in lactococci, these systems can exhibit significant basal activity. This can be circumvented by integrating the histidine kinase and response regulator genes into the chromosome, thereby restricting the expression system to a specifically designed host strain.

[0101] In another embodiment, the expression system can be based on genes and promoters involved in producing class II bacteriocin sakacin A (sap gene) by the sakacin A regulator or sakacin P (spp gene) by the sakacin P regulator. Such vectors are called pSIP vectors, contain promoter elements derived from sakacin A or sakacin P structural genes, and have engineered NcoI sites for translational fusion cloning. A variety of such vectors containing different promoters from regulators and / or different replicons are described in the above-mentioned paper by Sorvig et al., and any of these vectors can be used as the basis for recombinant plasmids of the present invention.

[0102] In representative embodiments, the promoter may be P from the sakacin A or P regulon. sapA , P sppA or P orfX Promoters, and their related or homologous regulatory genes.

[0103] In a particularly preferred embodiment, the plasmid contains the pSH71 replicon, the P from the sakacin P regulator, and the pSIP411 vector described in Sorvig et al., 2005. orfX Promoter and homologous regulatory gene. Plasmid pSIP411 is named pLAB112 in the present application. The inducing agent used in such embodiments is preferably an activation peptide based on the peptide SppIP, for example an activation peptide having a sequence shown in SEQ ID NO:19 or an amino acid sequence having at least 80% (or more specifically at least 85%, 90% or 95%) sequence identity thereto. In a specific embodiment, the plasmid is derived from a plasmid named pLAB112, which has a nucleotide sequence as shown in SEQ ID NO:20 (the corresponding amino acid translation is shown in SEQ ID NO:34).

[0104] The use of an inducible promoter (or inducible expression system) can provide the following advantages: in the intestinal environment, that is, when the bacteria are applied to the subject, the expression of the protein is more controllable, especially the expression time is longer. In order to obtain better results in the treatment or prevention of intestinal diseases caused by therapy, it is advantageous to express the protein by bacteria at the site of intestinal disease for a period of time, for example, at least 40, 45, 50, 55 or 60 minutes, in particular at least one hour or longer. Therefore, the protein can be expressed in a limited, determined or extended time period. The results reported in WO2016 / 102660 show that the protein can be expressed on the wound surface for about one hour. In some embodiments, the bacteria can be optimized to express the protein for 2, 3 or 4 hours or more.

[0105] Therefore, continuous expression and delivery of proteins is desired, which can be achieved by using engineered LABs. "Continuous" or "extended" refers to expressing and thus delivering a protein over a period of time, such as at least one hour (or similarly, as described above). In particular, this makes the protein more effective over a period of time compared to direct administration of the protein (i.e., as a protein product rather than expressed by bacteria).

[0106] As described above, the nucleotide sequence encoding the protein can be codon optimized for expression in LAB. Therefore, in a preferred embodiment, the nucleotide sequence encoding the protein can be selected from the codon-optimized nucleotide sequences encoding mouse CXCL12, human CXCL12, mouse CXCL17, human CXCL17, mouse Ym1 and human Ym1 as shown in SEQ ID NO: 1, 4, 7, 10, 13 and 16, respectively, or a nucleotide sequence having at least 80% sequence identity thereto.

[0107] Thus, in a representative embodiment, the recombinant plasmid can be selected from the group consisting of mLrCK1 comprising the nucleotide sequence shown in SEQ ID NO:1 (the corresponding amino acid translation is shown in SEQ ID NO:28); mLrCK1.4 comprising the nucleotide sequence shown in SEQ ID NO:1; mLrCK1.7 comprising the nucleotide sequence shown in SEQ ID NO:1; hLrCK1 comprising the nucleotide sequence shown in SEQ ID NO:4 (the corresponding amino acid translation is shown in SEQ ID NO:29); mLrCK2 comprising the nucleotide sequence shown in SEQ ID NO:7 (the corresponding amino acid translation is shown in SEQ ID NO:30); hLrCK2 comprising the nucleotide sequence shown in SEQ ID NO:10 (the corresponding amino acid translation is shown in SEQ ID NO:31); hLrMP1 comprising the nucleotide sequence shown in SEQ ID NO:13 (the corresponding amino acid translation is shown in SEQ ID NO:32); and mLrMP2 comprising the nucleotide sequence shown in SEQ ID NO:16 (the corresponding amino acid translation is shown in SEQ ID NO:33).

[0108] In some embodiments, the protein is encoded by a nucleotide sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity to the nucleotide sequence of the following codon-optimized insert fragments mLrCK1 (i.e., the nucleotide sequence set forth in SEQ ID NO: 1), mLrCK1.4 (i.e., the nucleotide sequence set forth in SEQ ID NO: 1), mLrCK1.7 (i.e., the nucleotide sequence set forth in SEQ ID NO: 1), hLrCK1 (i.e., the nucleotide sequence set forth in SEQ ID NO: 4), mLrCK2 (i.e., the nucleotide sequence set forth in SEQ ID NO: 7), hLrCK2 (i.e., the nucleotide sequence set forth in SEQ ID NO: 10), hLrMP1 (i.e., the nucleotide sequence set forth in SEQ ID NO: 13), and mLrMP2 (i.e., the nucleotide sequence set forth in SEQ ID NO: 16).

[0109] The sequence identity of nucleotide molecules can be determined by methods and software known in the art and widely available, for example, by FASTA searching using the GCG package, using default values ​​and a variable pam factor, a gap creation penalty set to 12.0, a gap extension penalty set to 4.0, and a window of 6 nucleotides.

[0110] Such sequence identity-related nucleotide sequences may be functionally equivalent to the nucleotide sequences set forth in SEQ ID NO: 1, 4, 10, 13 or 16. If such nucleotide sequences encode polypeptides that are considered to be functional equivalents of the corresponding CXCL12, CXCL17 or Ym1 proteins, then these nucleotide sequences may be considered to be functionally equivalent. Specific functional equivalents are those that encode specific proteins as described above.

[0111] The bacteria can be administered in any convenient or desired manner, such as orally, or by direct administration to the gastrointestinal tract, such as rectally, or by direct injection or infusion or application or introduction of a pharmaceutical composition or dressing or device containing the bacteria. In a specific embodiment, the bacteria are administered orally.

[0112] The bacteria may be formulated or prepared in any convenient or desired manner for administration by any of the above-mentioned routes, according to procedures and methods of use well known and conventional in the art. Thus, in addition to pharmaceutical compositions, medical devices, dressings, etc., the products used herein may be formulated and provided as or in nutritional supplements or foods, such as functional foods.

[0113] Oral administration forms include powders, tablets, capsules, solutions, etc. In addition, the bacteria can be placed (eg, coated) on the surface of medical devices such as implants (eg, prosthetic implants), tubes, wires, or catheters.

[0114] The bacteria may be provided in any convenient or desired form, for example as an active or growing culture or in lyophilized or freeze-dried form.

[0115] In general, for administration herein, LAB can be conveniently provided as an enteric formulation, i.e., as a formulation that is free from digestion in the stomach and designed to release the LAB in the intestine. Therefore, the formulation can be resistant to gastric juice. It can be designed to release the LAB at a neutral pH. Methods for preparing enteric formulations and compositions are known in the art and described in the literature, for example, using coatings and / or excipients. Specifically, the composition containing the LAB can have an enteric coating. Such coatings are commercially available, including, for example, enteric coatings produced by Evonik Health Care under the brand name Eudragit.

[0116] In one embodiment, the LAB may be provided as or in a tablet, capsule, or microgranules having an enteric coating.

[0117] The composition comprising LAB may also comprise an inducer (where an inducible promoter is used). This may be provided as part of the product (e.g. incorporated into or contained in a tablet or capsule) or may be provided separately, e.g. as part of a kit or combination product, as defined above.

[0118] When co-formulated in a product, the bacteria and the inducer can be provided in a form where the bacteria and the inducer are separated and brought together (or in contact with each other) when used. For example, the bacteria and the inducer can be located in separate compartments, which are brought together (e.g., in contact or mixed) when used, or can be separated by a barrier (e.g., a membrane or other partition) that can be broken or collapsed or opened when used.

[0119] Alternatively, the inducer can be formulated and provided separately (e.g., in a kit that also contains bacteria or a product containing bacteria), and the inducer and bacteria (or product containing bacteria) can be placed together (e.g., in contact) during use. This can be done before, during, or after administration to the subject. For example, the product containing bacteria can be administered first, and then the inducer can be added or applied to the bacteria. In another embodiment, the bacteria and inducer can be premixed before administration (e.g., just before or immediately before administration) or during administration.

[0120] When the bacteria are provided in a lyophilized or freeze-dried form, it may be necessary to reconstitute or resuspend the bacteria prior to administration (e.g., before or during use). However, for use herein, the bacteria are provided in a lyophilized or freeze-dried form so that they can be reconstituted by body fluids upon release in the gastrointestinal tract.

[0121] For convenient use herein, LAB can be formulated into enteric-coated capsules containing freeze-dried bacteria and freeze-dried inducers.

[0122] Alternatively, the tablet may contain at least two separate compartments, one of which contains freeze-dried bacteria and the other of which contains an inducer and optionally a liquid. The tablet is squeezed before ingestion to rupture the inner membrane separating the two compartments and mix the contents together.

[0123] The engineered LABs can be used as proposed herein to treat therapy-induced enteropathy in an advantageous manner. It is believed that superior therapeutic effects can be obtained compared to existing treatments, particularly compared to steroid therapy. Indeed, therapy-induced enteropathy may become resistant or refractory to steroid therapy, and thus the present proposal provides an opportunity to treat a previously difficult-to-treat class of patients, such as patients diagnosed with steroid-refractory ICI-induced colitis.

[0124] Furthermore, the currently proposed treatment approach has the advantage of sparing the subject from receiving steroid therapy.

[0125] Representative embodiments are further described with reference to the following non-limiting examples and figures. BRIEF DESCRIPTION OF THE DRAWINGS

[0126] Figure 1 Effects of ILP100 on PD-1 inhibitor-induced colitis in mice. Hematoxylin and eosin-stained mouse colon tissue sections (A), crypt damage scores (B), and average crypt damage score graphs (C). Mice were subcutaneously inoculated with breast cancer tumor cells. Treatment was initiated when the tumors reached a specific size. Group A: no treatment for 3 weeks. Group B: anti-PD-1 antibody + isotype control monoclonal antibody (mAb) treatment for 3 weeks. Group C: anti-PD-1 antibody isotype control mAb treatment for 3 weeks + ILP100 treatment for 1 week (week 3). One-way ANOVA multiple comparisons followed by Holm-Sidak post hoc test. Mice / sample per group: n = 4.

[0127] Figure 2 Effect of ILP100 on PD-1-induced epithelial cell shedding in mice. The figure shows epithelial cell shedding measured at termination in mice treated with isotype control, anti-PD-1, or anti-PD-1 and R2LC_CXCL12 in sequence. One-way ANOVA multiple comparisons followed by Holm-Sidak post hoc test. Mice / sample per group: n = 4 to 6.

[0128] Figure 3 : The effect of ILP100 on PD-1 and PDL-1-induced colon shortening in mice. The figure shows the colon length (cm) of mice treated with isotype control antibody and vehicle, PD-1 inhibitor and vehicle, PD-1 inhibitor and ILP100, PD-L1 inhibitor and vehicle, or PD-L1 inhibitor and ILP100.

[0129] Figure 4 The effect of ILP100 on the incidence of colonic erosion / ulceration induced by PD-1 inhibitor in mice. The figure shows the incidence of colonic erosion / ulceration measured at the end of the experiment in mice treated with isotype control, anti-PD-1, or anti-PD-1 and R2LC_CXCL12 in sequence.

[0130] Figure 5 The effect of WT_R2LC and R2LC_hCXCL12 on colitis in mice induced by the combination of DSS and PD-1 inhibitors. The figure shows the disease activity index (A), weight loss (B), intestinal bleeding score (C), stool consistency score (D), colon length (E), colon weight (mg) (F) and the ratio of colon weight to colon length (G) of mice treated with vehicle (DSS+ICI), WT_R2LC (DSS+ICI+WT_R2LC) or R2LC_hCXCL12 (DSS+ICI+R2LC_hCXCL12). Figure 5 The untreated (UT) group in E to G was included as a reference and did not participate in the statistical tests.

[0131] Figure 6 The effects of ILP100, WT_R2LC, anti-TNF and anti-α4β7 on DSS-induced colitis in mice. Figure 6 A, B and E show the disease activity index (A), colon length (cm) (B) and the incidence of colonic erosions / ulcers measured at termination (E) in healthy mice and mice treated with DSS alone (DSS), ILP100 (DSS+R2LC_CXCL12) or WT_R2LC (DSS+WT_R2LC). Figure 6 C and D show the disease activity index (C) and colon length (cm) (D) of healthy mice and mice treated with DSS (DSS), ILP100 (DSS+R2LC_CXCL12), anti-TNF (DSS+anti-TNF), or anti-α4β7 (DSS+anti-α4β7) alone. Mice / sample per group: n=22 to 32 for A and C; n=4 for B and D.

[0132] Example

[0133] Example 1: Preparation of Lactobacillus reuteri expressing CXCL12 (ILP100)

[0134] As described in Example 1 of WO2016 / 102660, the Lactobacillus reuteri R2LC strain was genetically modified with a plasmid containing a nucleotide sequence encoding human CXCL12. The modified strain is designated herein as ILP100.

[0135] Briefly, the sequence of hCXCL12 was codon optimized for expression in LAB and the resulting sequence (SEQ ID NO: 4) was introduced into plasmid pLAB112 (SEQ ID NO: 20), which corresponds to Plasmid pSIP411 described in Construction of vectors for inducible gene expression in Lactobacillus sakei and L plantarum. FEMS Microbiol Lett. 2003; 229(1): 119-126.

[0136] The resulting plasmid named hLrCK1 (pLAB112 with optimized hCXCL12-1α insert) was transformed into Lactobacillus reuteri R2LC strain, and positive clones of the construct were collected. Plasmid hLrCK1 in the positive clone colonies was verified by sequence analysis. The positive clone was named ILP100 strain.

[0137] Example 2: ILP100 treatment reduces crypt damage in mice with PD-1 inhibitor-induced colitis

[0138] The effect of ILP100 on PD-1 inhibitor-induced colitis in mice was studied in three experimental groups: A, B, and C. Figure 1 ). On day 0, female BALB / c mice were orthotopically inoculated with 7000 4T1 cells. Tumor size was monitored twice a week in this study. Animals received A) isotype control mAb treatment once a week for three weeks; B) anti-PD-1 antibody treatment once a week for three weeks; or C) anti-PD-1 antibody treatment once a week for three weeks and received ILP100 treatment by oral gavage 7 days before termination of the experiment. At the termination of the experiment, blood smears and Swiss-rolls for fixing the colon and small intestine were prepared for each animal and fixed with 4% PFA.

[0139] Swiss rolls of colon and small intestine tissue were paraffin-embedded, sectioned, and stained with hematoxylin. The slides were scanned using a microscope ( Figure 1 A). Image files were analyzed blindly, with the key kept by a person not involved in the image analysis or interpretation of the results. Images were analyzed histopathologically, including assessment of crypt damage. Each image was evenly divided into squares of y × y mm2, and histological scores were scored from 0 to 3 ( Figure 1 B) Calculate the mean value for each tissue corresponding to one animal. Then perform an open-label analysis. Calculate the mean and SEM for each group. The results are shown in Figure 1 As shown in C.

[0140] Figure 1 C shows that the average crypt damage score of group B was higher than that of group A, indicating that 3 weeks of PD-1 treatment caused significant damage to the intestine. Compared with group B, the average crypt damage score of group C was significantly reduced, indicating that ILP100 treatment of group C mice with PD-1-induced colitis was effective.

[0141] Example 3: ILP100 treatment reduces epithelial cell shedding in mice with PD-1 inhibitor-induced colitis damage

[0142] The effect of ILP100 treatment on epithelial cell shedding in female Balb / C mice treated with PD-1 inhibitors was investigated.

[0143] The effect of ILP100 on PD-1 inhibitor-induced colitis in mice was investigated in three experimental groups ( Figure 2 ). On day 0, mice were inoculated intraperitoneally with 7,000 4T1 cells. Tumor size was monitored twice weekly in this study. Animals received weekly treatment with an isotype control mAb for three weeks; weekly treatment with an anti-PD-1 antibody for three weeks; or weekly treatment with an anti-PD-1 antibody for three weeks, followed by daily treatment with ILP100 (orally administered by gavage) for seven days before termination of the experiment.

[0144] At the end of the experiment, the colon was collected and rolled into a Swiss roll. The tissue was paraffin-embedded, sectioned, and stained with hematoxylin and eosin. The length of the erosion and ulceration areas in each section was measured. Erosions were defined as areas without epithelial cells but with intact crypt architecture, and ulcers were defined as areas without epithelial cells and no crypt architecture remained. Because the ulcerated areas were few and very small, the two parameters were combined and defined as epithelial cell shedding. Figure 2 The results showed that the group of mice treated with a PD-1 inhibitor combined with ILP100 had less epithelial cell shedding compared to mice treated with vehicle. Figure 4 showed that mice treated with a PD-1 inhibitor combined with ILP100 had a reduced incidence of colonic erosions / ulcers.

[0145] In contrast to anti-PD1 antibodies (PD1 inhibitors), ILP100 treatment had no effect on tumor size in mice.

[0146] Example 4: ILP100 treatment reduces colitis in mice with PD-1 inhibitor and PD-L1 inhibitor-induced colitis Shortened colon

[0147] The effects of ILP100 treatment on colon length (indicating the development of fibrosis) in mice treated with PD-1 inhibitors and PD-L1 inhibitors were also investigated. Figure 3 The results showed that mice treated with isotype control and vehicle had the longest colon length at the end of the experiment. In contrast, mice treated with PD-1 inhibitor and vehicle, or PD-L1 inhibitor and vehicle, had significantly shorter colon lengths. However, the groups of mice treated with ILP100 in combination with PD-1 inhibitor or PD-L1 inhibitor showed a trend toward preserved colon length and reduced colon shortening.

[0148] In addition, it was observed that mice treated with anti-PD1 did not show traditional symptoms of colitis as measured by the disease activity index, including weight loss, stool consistency, and blood in the stool. However, the mice showed severe fibrosis development (20% shortening of the colon), and a significant increase in erosions and ulcers, which was reversed by ILP100 treatment even for a short period of time.

[0149] Example 5: Preparation and coating of capsules containing SppIP and ILP100

[0150] SppIP was dissolved in a solution containing 15% glucose. To control the content, the peptide solution was dispensed into a well plate and lyophilized in a tablet-like form. The SppIP lyophilized tablets were then added to capsules together with lyophilized ILP100, and the capsules were coated with a coating polymer (Eudragit L 30D-55) by roller coating.

[0151] Example 6: ILP100 treatment reduces colonic inflammation in mice with combined DSS and PD-1 inhibitor-induced colitis Inflammatory symptoms

[0152] The effects of ILP100 (R2LC hCXCL12) and wild-type R2LC treatment on disease activity index (DAI), weight loss, intestinal bleeding, stool consistency, colon length, colon weight, and ratio of colon weight to colon length were investigated in mice treated with a combination of DSS and a PD-1 inhibitor (anti-CTLA-4) to induce colitis. Administration of ILP100 during overt inflammation significantly improved colitis symptoms assessed by DAI compared to mice treated with vehicle or wild-type R2LC. Figure 5 In addition, the clinical signs of colitis in mice treated with ILP100 were significantly reduced compared with those in mice treated with vehicle or wild-type R2LC ( Figure 5 B to G) was improved. Colon weight may be related to edema as part of inflammation and can be used as a marker of inflammation (the higher the weight, the more severe the inflammation). Colon length is an indicator of fibrosis (the shorter the colon length, the more severe the fibrosis and inflammation). Therefore, the weight / length ratio is a good indicator of the induction of colitis.

[0153] Example 7: ILP100 improves DSS-induced colitis and improves symptoms, and its efficacy is better than or equivalent to existing Ulcerative colitis treatment

[0154] Mice were treated with 3% DSS for 6 days to induce colitis. Animals were then treated with vehicle (H2O), WT_R2LC or ILP100 (R2LC hCXCL12) by gavage three times a day for 6 days on day 6, or anti-TNF or anti-α4β7 by intraperitoneal injection once a day. At the end of the experiment, the colon was fixed and processed as described in Example 2.

[0155] The effects of ILP100 and wild-type R2LC treatment on DSS-induced colitis in mice were investigated. Figure 6 A and B). Administration of ILP100 during overt inflammation significantly improved colitis symptoms assessed by DAI compared with vehicle-treated and wild-type R2LC-treated mice ( Figure 6 A) In addition, the colons of mice treated with ILP100 were significantly longer compared to mice treated with vehicle or wild-type R2LC.

[0156] The effects of ILP100 treatment on DSS-induced colitis were compared with the current standard of care treatments for IBD (anti-TNF and anti-α4β 7; Figure 6 C and D) were compared. Administration of ILP100 significantly improved colitis symptoms as assessed by DAI, outperforming the current standard of care treatment ( Figure 6 C). In addition, the colon length of mice treated with ILP100 was comparable to that of mice treated with anti-TNF and anti-α4β7 ( Figure 6D). Mice treated with ILP100(R2LC_hCXCL12) had the lowest DAI (not significant) over the entire study compared to mice treated with anti-TNF and anti-α4β7, and were the only animals to have a significant reduction in colon shortening compared to controls. Intestinal bleeding was reduced more rapidly in animals treated with ILP100(R2LC_hCXCL12) compared to the other treatments.

[0157] The remarkable positive effect of the engineered LAB (ILP100(R2LC CXCL12)) was surprising given that the action of the engineered bacteria occurs at a local level.

[0158] sequence

[0159] Summary of Sequence Listing

[0160]

Claims

1. An engineered lactic acid bacteria (LAB) for treating therapy-induced enteropathy in a subject, wherein the lactic acid bacteria are engineered to express a mammalian protein that promotes resolution of inflammation and / or wound healing.

2. The engineered LAB for use according to claim 1, wherein the protein that promotes inflammation resolution and / or wound healing is an immunomodulatory protein that regulates immune cell activity.

3. The engineered LAB for use according to claim 1 or 2, wherein the LAB is capable of expressing a protein selected from the group consisting of CXCL12, CXCL17 and Ym1.

4. The engineered LAB for use according to any one of claims 1 to 3, wherein the therapy-induced bowel disease is a tumor therapy-induced bowel disease.

5. An engineered LAB for use according to any one of claims 1 to 4, wherein the therapy-induced enteropathy is immune checkpoint inhibitor-induced (ICI-induced) enteropathy or radiation-induced enteropathy.

6. An engineered LAB for use according to any one of claims 1 to 6, wherein the protein is selected from: (i) murine CXCL12-1α having an amino acid sequence as shown in SEQ ID NO: 3 or 2, or an amino acid sequence having at least 80% sequence identity thereto; (ii) human CXCL12-1α having an amino acid sequence as shown in SEQ ID NO: 6 or 5, or an amino acid sequence having at least 80% sequence identity thereto; (iii) murine CXCL17 having an amino acid sequence as shown in SEQ ID NO: 9 or 8, or an amino acid sequence having at least 80% sequence identity thereto; (iv) human CXCL17 having an amino acid sequence as shown in SEQ ID NO: 12 or 11, or an amino acid sequence having at least 80% sequence identity thereto; (v) murine Ym1 having an amino acid sequence as shown in SEQ ID NO: 15 or 14, or an amino acid sequence having at least 80% sequence identity thereto; and (vi) human Ym1 as shown in SEQ ID NO: 18 or 17, or an amino acid sequence having at least 80% sequence identity thereto.

7. An engineered LAB for use according to any one of claims 1 to 6, wherein the LAB is transformed with a plasmid expressing the protein.

8. The engineered LAB for use according to claim 7, wherein the plasmid comprises one or more nucleotide sequences encoding one or more of the proteins under the control of an inducible promoter.

9. The engineered LAB for use according to claim 7 or 8, wherein the plasmid comprises an inducible promoter and regulatory elements of the nisin regulon, sakacin A regulon or sakacin P regulon from lactic acid bacteria.

10. The engineered LAB for use according to any one of claims 7 to 9, wherein the inducible promoter is the PorfX promoter from the sakacin P regulon.

11. An engineered LAB for use according to any one of claims 7 to 10, wherein the plasmid is derived from a plasmid designated pSIP411.

12. An engineered LAB for use according to any one of claims 1 to 11, wherein the LAB is engineered by introducing a nucleotide sequence encoding the protein, the nucleotide sequence being codon-optimized for expression in lactic acid bacteria.

13. An engineered LAB for use according to any one of claims 1 to 12, wherein the LAB comprises one or more nucleotide sequences selected from the group consisting of: a nucleotide sequence comprising the sequence SEQ ID NO: 1, SEQ ID NO: 4, SEQ ID NO: 7, SEQ ID NO: 10, SEQ ID NO: 13 and SEQ ID NO: 16, or a nucleotide sequence having at least 80% sequence identity with any of the above sequences.

14. An engineered LAB for use according to any one of claims 1 to 13, wherein the LAB belongs to the genus Lactobacillus.

15. An engineered LAB for use according to any one of claims 1 to 14, wherein the LAB is a strain of Lactobacillus reuteri.

16. The engineered LAB for use according to claim 15, wherein the LAB is Lactobacillus reuteri R2LC strain.

17. An engineered LAB for use according to any one of claims 1 to 16, wherein the LAB is provided as an orally administrable pharmaceutical composition comprising the LAB and one or more pharmaceutically acceptable excipients.

18. An engineered LAB for use according to any one of claims 1 to 17, wherein the LAB is lyophilized.

19. The engineered LAB for use according to claim 17 or 18, wherein the LAB is provided in the form of an enteric-coated capsule.

20. The engineered LAB for use according to any one of claims 17 to 19, wherein the LAB expresses the protein under the control of an inducible promoter, the pharmaceutical composition or capsule further comprising an inducer of the promoter.